Square Pharmaceuticals PLC. (DSE: SQURPHARMA)

Market Cap	192.45B
Revenue (ttm)	70.04B
Net Income (ttm)	21.02B
Shares Out	886.45M
EPS (ttm)	23.71
PE Ratio	9.16
Forward PE	8.48
Dividend	11.00 (5.08%)
Ex-Dividend Date	Nov 24, 2024

Volume	179,664
Average Volume	214,933
Open	n/a
Previous Close	216.40
Day's Range	215.70 - 217.80
52-Week Range	197.20 - 249.80
Beta	0.23
RSI	51.18
Earnings Date	Jan 29, 2025

About DSE: SQURPHARMA

Square Pharmaceuticals PLC., together with its subsidiaries, manufactures, markets, and sells pharmaceutical products in Bangladesh and internationally. The company offers pharmaceutical products comprising alimentary preparations, amoebocides, analgesics, anti-aphthous ulcer, anti-erectile dysfunction, anti-gout, anti-hyperkalemia, anti-osteoarthritis, anti-thyroid, anti-ulcerants, anthelmintics, antiallergies, antianemics, antiasthma, antibiotics, antidiabetics, antifibrinolytics, antihemorrhoidals, antihistamines, antiosteoporotics, antioxid...

• Industry: Pharmaceutical Preparations
• Founded: 1958
• Employees: 12,453
• Stock Exchange: Dhaka Stock Exchange
• Ticker Symbol: SQURPHARMA

Financial Performance

In 2024, SQURPHARMA's revenue was 70.10 billion, an increase of 15.47% compared to the previous year's 60.71 billion. Earnings were 20.93 billion, an increase of 10.25%.